Equibles does not estimate personal net worth.
Get an email with a short summary when Lineage Cell Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get LCTX alertsJill Howe is recorded as CFO at Lineage Cell Therapeutics, Inc. (LCTX). Jill Howe has spoken on 12 earnings calls across 1 company, most recently for Lineage Cell Therapeutics, Inc. on August 6, 2026. Lineage Cell Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Lineage Cell Therapeutics, Inc. includes Brian M. Culley (CFO and Board Member), Jill A. Howe (CFO and Board Member), Alexandra Hernandez (Chief Accounting Officer) and 7 others.
“I'll begin with an update on our cash runway. As of June 30th, 2026, we had $50.8 million in cash, cash equivalents, and marketable securities, which we expect will fund planned operations into the third quarter of 2028 and that is one quarter longer than the runway we reported on our last call.”
“As of March 31, 2026, our overall cash position was $53.4 million. This capital is expected to support our planned operations into Q2 of 2028.”
“Before presenting our financial results, I want to address some points that may have caught your attention. The reported net loss for the full year is approximately $45 million higher than in 2024.”
“As of September 30th, 2025, our overall cash position was $40.5 million. This amount is expected to support our planned operations into Q2 of 2027, which is one quarter longer than we guided to on our last call.”
“As of June 30, 2025, our overall cash position was $42.3 million. This capital is expected to support our planned operations into Q1 of 2027, which we believe will allow us to reach multiple milestones and events.”
Biotechnology · Healthcare
CFO
